Effects of Sarcopenia on Early Postoperative Outcomes in Patients Undergoing Surgical Treatment for Gastric Cancer
- Conditions
- ComplicationSarcopeniaGastric CancerMalnutrition; Cachexia
- Interventions
- Other: No intervention
- Registration Number
- NCT03958032
- Lead Sponsor
- Karadeniz Technical University
- Brief Summary
We aimed to establish the effects of sarcopenia on postoperative complications among patients undergoing surgical treatment for gastric cancer
- Detailed Description
Among gastrointestinal disease, gastric cancer is a malignancy which is diagnosed predominantly in advanced stages, mostly accompanied with malnutrition when diagnosed, has aggressive behavior with poor oncological outcomes. The only option for curative treatment is surgical resection in this malignancy; however, the surgical procedure itself causes high morbidity and mortality rates. Therefore, physicians combine various treatment modalities and risk assessment to decrease complication and mortality rates.
Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life, and death. For the diagnosis of sarcopenia, using the presence of both low muscle mass and decreased muscle function (strength or performance) is recommended. Previous studies showed that colorectal or pancreatic cancer accompanied with sarcopenia has adverse effects on not only for short term and also for long term outcomes. The majority of studies regarding gastric cancer was published from Eastern countries owing to their high incidence. There are few studies from western countries which are mostly retrospective and does not meet the diagnostic criteria of sarcopenia. In the western population, there is no high-quality evidence so far regarding the impact of sarcopenia on early outcomes of gastric cancer surgical treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 185
- Patients undergoing gastric surgery for gastric cancer
- Histologically proven gastric adenocarcinoma
- Patients over 18 years
- Patients who agreed to participate in the study
- patients treated by non-surgical treatment such as endoscopic treatment, palliative chemotherapy)
- patients received palliative surgery without gastric resection (bypass procedures)
- patients required thoracotomy/thoracoscopy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Participants with gastric cancer No intervention All consecutive patients undergoing surgery due to gastric cancer will be included in this study.
- Primary Outcome Measures
Name Time Method Postoperative complications within 30 days after surgery complications graded by Clavien-Dindo Complication Classification System
- Secondary Outcome Measures
Name Time Method Readmission rate within 30 days after surgery readmission to the hospital because of the adverse events after discharge
Length of hospital stay up to 90 days time interval from the date of operation to the date of discharge
Mortality within 30 days after surgery Dying after surgery
Psoas muscle mass volume one day before surgery muscle mass volume of Psoas muscle with 3D reconstruction
Incidence of sarcopenia one day before surgery Sarcopenia consensus defined by The European Working Group on Sarcopenia in Older People
Muscle mass volume one day before surgery muscle mass volume of a cross-sectional computerized- tomography image of the L3, corrected for patient height resulting in L3 muscle index.
Muscle strength one day before surgery evaluated by handgrip strength test (with digital dynamometer)
Physical performance one day before surgery evaluated by 4-meter gait speed test
Major complication within 30 days after surgery grade 3 or higher complications graded by Clavien-Dindo Complication Classification System
Trial Locations
- Locations (1)
Karadeniz Technical University, Faculty of Medicine
🇹🇷Trabzon, Turkey